Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Genprex Inc (GNPX)

Genprex Inc (GNPX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,324
  • Shares Outstanding, K 15,843
  • Annual Sales, $ 0 K
  • Annual Income, $ -12,370 K
  • 60-Month Beta 1.45
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.42
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.61
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/19/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.22
  • Number of Estimates 1
  • High Estimate -0.22
  • Low Estimate -0.22
  • Prior Year -0.15
  • Growth Rate Est. (year over year) -46.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.42 +19.05%
on 10/17/19
0.92 -45.40%
on 09/26/19
-0.38 (-42.86%)
since 09/20/19
3-Month
0.42 +19.05%
on 10/17/19
1.20 -58.33%
on 09/11/19
-0.57 (-53.27%)
since 07/22/19
52-Week
0.42 +19.05%
on 10/17/19
2.26 -77.88%
on 03/14/19
-1.25 (-71.43%)
since 10/22/18

Most Recent Stories

More News
Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers

Advances in biotechnology look to deliver promising new treatment options against breast cancer. Independent researchers have found that Genprex Inc.'s (NASDAQ: GNPX) (GNPX Profile) TUSC2 prevented tumor...

LLY : 109.80 (+1.75%)
RHHBY : 36.4500 (-0.76%)
ABBV : 78.24 (+1.22%)
AZN : 44.11 (+0.89%)
GNPX : 0.51 (-3.77%)
Gene Therapy Treatments Offer Hope for Cancer Patients

Recent developments in gene therapy hold out hope for the treatment of a wide range of diseases, including fatal lung cancer.

PFE : 36.52 (+0.16%)
GILD : 66.08 (+1.33%)
SRPT : 85.68 (-1.09%)
MRK : 81.57 (-3.49%)
GNPX : 0.51 (-3.77%)
Record Revenues, Milestone Achievements Indicate Strength, Potential of Biotech Sector

Biotech and biopharma industry leaders are posting record financials and hitting milestone markers in their research and growth, good indicators of a strong market with potential for robust returns on...

CELGZ : 0.46 (+2.22%)
AMGN : 204.56 (+0.80%)
BIIB : 282.15 (+26.24%)
CELG : 105.01 (+1.56%)
BMY : 54.96 (+3.31%)
GNPX : 0.51 (-3.77%)
Potential Blockbuster Gene Therapy Programs to Watch in 2019

Several revolutionary gene therapies appear to be on the verge of delivering remarkable remedies for diseases that have previously been viewed as untreatable.

SGMO : 8.55 (+0.94%)
QURE : 43.49 (+0.16%)
BLUE : 88.87 (-2.85%)
LPTX : 1.17 (+2.63%)
GNPX : 0.51 (-3.77%)
Advanced Medical Technologies Provide Unprecedented Targeting in Cancer Therapy

Pharmaceutical companies are now employing advanced medical breakthroughs and new technologies, including gene therapies and nanoparticle engineering, to fight every type of cancer.

PFE : 36.52 (+0.16%)
TOCA : 0.61 (-6.15%)
NVS : 87.01 (+0.52%)
BOLD : 27.02 (-0.59%)
GNPX : 0.51 (-3.77%)
Making Profits, Saving Lives With Gene Therapy

After thirty years of development, gene therapy is seeing a surge of progress and profitability.

ONCE : 99.87 (-0.94%)
DYAI : 6.61 (+0.15%)
TROV : 1.71 (+62.86%)
NVS : 87.01 (+0.52%)
GNPX : 0.51 (-3.77%)
Genprex Appoints John N. Bonfiglio, PhD, to Board of Directors

Genprex, Inc. (NASDAQ: GNPX) a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced...

OGEN : 0.44 (+2.33%)
TPIV : 8.34 (+0.60%)
GNPX : 0.51 (-3.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade GNPX with:

Business Summary

Genprex Inc. operates as a biotechnology company. It discovers and develops immunogene therapies for cancer treatment as well as clinical research, gene therapies, consulting and other related medical services. The company's initial product candidate is Oncoprex(TM) immunogene therapy which treats non-small...

See More

Key Turning Points

2nd Resistance Point 0.62
1st Resistance Point 0.57
Last Price 0.51
1st Support Level 0.47
2nd Support Level 0.41

See More

52-Week High 2.26
Fibonacci 61.8% 1.56
Fibonacci 50% 1.34
Fibonacci 38.2% 1.12
Last Price 0.51
52-Week Low 0.42

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar